{"id":"W2979041297","doi":"10.1016/j.cllc.2019.09.007","title":"Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Servier; Les Laboratories Pierre Fabre; Takeda Pharmaceutical Company; AbbVie; Roche; Novartis; Meso Scale Diagnostics; Sanofi; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Canadian Asian Studies Association; AstraZeneca; Bristol-Myers Squibb; Bayer","keywords":"Medicine; Osimertinib; Lung cancer; Liquid biopsy; Biopsy; Acquired resistance; Cancer; Pathology; Oncology; Cancer research; Internal medicine; Adenocarcinoma; ROS1","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001305517,0.00147086,0.002033502,0.0002464767,0.000267931,0.001105252,0.0007162382,0.001070651,0.002795921],"category_scores_gemma":[0.001068441,0.0003572984,0.001402876,0.0002613009,0.0008102441,0.0009553983,0.0004134566,0.003051168,0.0005971014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007686789,"about_ca_system_score_gemma":0.0008447172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006128828,"about_ca_topic_score_gemma":0.001792217,"domain_scores_codex":[0.9996048,0.0002153511,0.00001175428,0.00007413088,0.00002741333,0.00006652797],"domain_scores_gemma":[0.9992649,0.000163391,0.000164415,0.00009174807,0.00004520089,0.0002703826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8632083,0.01777042,0.01724272,0.0003571138,0.001573257,0.0002151763,0.0002040751,0.001900241,0.03049004,0.0004302362,0.0024092,0.06419937],"study_design_scores_gemma":[0.579116,0.3601966,0.04454998,0.00005461651,0.001237932,0.0005744243,0.000188342,0.003090891,0.00636647,0.0006447779,0.003907247,0.00007277594],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958423,0.001038011,0.0002930308,0.0003196889,0.00005334773,0.0005001584,0.0006592571,0.00002889213,0.001265375],"genre_scores_gemma":[0.9929848,0.0008431455,0.0007784691,0.0005611014,0.00006838189,0.0005173796,0.001875257,0.00001859483,0.002352875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002795921,"threshold_uncertainty_score":0.00935334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02327523870040962,"score_gpt":0.4492838678513752,"score_spread":0.4260086291509656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}